POSB25 Public Health Benefit of Switching to High Dose Quadrivalent Vaccine for Influenza Seasonal Vaccination in Portuguese Elderly Population.

Borges, Margarida; Lopes, Ricardo; Bricout, Hélène; Martins, Maércio; Courville, Caroline de; Miguel, L Silva

doi:10.1016/j.jval.2021.11.135

Cited by 1 publication

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… rVE as used in base-case analyses of HD-TIV/HD-QIV compared with TIV/QIV or aTIV/aQIV [ 65 , 66 , 67 , 68 , 69 , 70 , 71 , 72 , 73 , 74 , 75 , 76 , 77 , 78 , 79 , 80 , 81 ]. Note: no value indicates that a comparison was not evaluated.…”

Section: Cost-effectiveness Studies With Enhanced Influenza Vaccinesmentioning

confidence: 99%

“…The rVE estimate of 24.2% for HD-TIV/HD-QIV versus TIV/QIV for LCI cases, based on results from the FIM12 RCT [50], was consistently used in CEA comparing HD-TIV/HD-QIV versus TIV/QIV, and used in CEA that indirectly compared the rVE of HD-TIV/HD-QIV versus aTIV/aQIV (Tables 2B and 3B; Figure 2). [65][66][67][68][69][70][71][72][73][74][75][76][77][78][79][80][81]. Note: no value indicates that a comparison was not evaluated.…”

Section: Comparison Between Cea For Enhanced and Standard Vaccinesmentioning

confidence: 99%

“…Figure 2. rVE as used in base-case analyses of HD-TIV/HD-QIV compared with TIV/QIV or aTIV/aQIV[65][66][67][68][69][70][71][72][73][74][75][76][77][78][79][80][81]. Note: no value indicates that a comparison was not evaluated.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Real-World Evidence in Cost-Effectiveness Analysis of Enhanced Influenza Vaccines in Adults ≥ 65 Years of Age: Literature Review and Expert Opinion

et al. 2023

View full text Add to dashboard Cite

Influenza vaccination can benefit most populations, including adults ≥ 65 years of age, who are at greater risk of influenza-related complications. In many countries, enhanced vaccines, such as adjuvanted, high-dose, and recombinant trivalent/quadrivalent influenza vaccines (aTIV/aQIV, HD-TIV/HD-QIV, and QIVr, respectively), are recommended in older populations to provide higher immunogenicity and increased relative vaccine efficacy/effectiveness (rVE) than standard-dose vaccines. This review explores how efficacy and effectiveness data from randomized controlled trials and real-world evidence (RWE) are used in economic evaluations. Findings from published cost-effectiveness analyses (CEA) on enhanced influenza vaccines for older adults are summarized, and the assumptions and approaches used in these CEA are assessed alongside discussion of the importance of RWE in CEA. Results from many CEA showed that adjuvanted and high-dose enhanced vaccines were cost-effective compared with standard vaccines, and that differences in rVE estimates and acquisition price may drive differences in cost-effectiveness estimates between enhanced vaccines. Overall, RWE and CEA provide clinical and economic rationale for enhanced vaccine use in people ≥ 65 years of age, an at-risk population with substantial burden of disease. Countries that consider RWE when making vaccine recommendations have preferentially recommended aTIV/aQIV, as well as HD-TIV/HD-QIV and QIVr, to protect older individuals.

show abstract

Section: Cost-effectiveness Studies With Enhanced Influenza Vaccinesmentioning

confidence: 99%

Section: Comparison Between Cea For Enhanced and Standard Vaccinesmentioning

confidence: 99%

See 1 more Smart Citation

Real-World Evidence in Cost-Effectiveness Analysis of Enhanced Influenza Vaccines in Adults ≥ 65 Years of Age: Literature Review and Expert Opinion

et al. 2023

View full text Add to dashboard Cite

show abstract

POSB25 Public Health Benefit of Switching to High Dose Quadrivalent Vaccine for Influenza Seasonal Vaccination in Portuguese Elderly Population.

Cited by 1 publication

References 0 publications

Real-World Evidence in Cost-Effectiveness Analysis of Enhanced Influenza Vaccines in Adults ≥ 65 Years of Age: Literature Review and Expert Opinion

Real-World Evidence in Cost-Effectiveness Analysis of Enhanced Influenza Vaccines in Adults ≥ 65 Years of Age: Literature Review and Expert Opinion

Contact Info

Product

Resources

About